<DOC>
	<DOCNO>NCT02609048</DOCNO>
	<brief_summary>A 12-week , double-blind , randomize , placebo-controlled , Phase 2 study , evaluate effect two dos MBX-8025 subject Primary Biliary Cirrhosis ( PBC ) inadequate response ursodeoxycholic acid ( UDCA )</brief_summary>
	<brief_title>Study Evaluate Effects Two Doses MBX-8025 Subjects With Primary Biliary Cirrhosis ( PBC )</brief_title>
	<detailed_description>Primary : To evaluate effect MBX-8025 Alkaline Phosphatase ( AP ) level Secondary : To evaluate safety tolerability MBX-8025 subject Primary Biliary Cirrhosis ( PBC ) To evaluate effect MBX-8025 Primary Biliary Cirrhosis ( PBC ) response criterion To evaluate effect MBX-8025 marker liver function , lipid , pruritus Quality Life ( QoL ) Exploratory : To evaluate effect MBX-8025 liver image biochemical marker may relevant pathophysiology PBC mechanism action drug</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>1 . Must give write informed consent ( sign date ) authorization require local law 2 . 18 75 year old ( inclusive ) 3 . Male female diagnosis PBC , least two follow criterion : History AP ULN least six month Positive AntiMitochondrial Antibodies ( AMA ) titer ( &gt; 1/40 immunofluorescence M2 positive enzyme link immunosorbent assay ( ELISA ) positive PBCspecific antinuclear antibody Documented liver biopsy result consistent PBC 4 . On stable recommend dose UDCA past twelve month 5 . AP ≥ 1.67 × ULN 6 . For female reproductive potential , use least one barrier contraceptive second effective birth control method study least two week last dose . For male subject , use appropriate contraception ( e.g. , condom ) , female partner reproductive potential become pregnant study least two week last dose 1 . A medical condition , PBC , investigator 's opinion would preclude full participation study confound result ( e.g. , cancer active treatment ) 2 . AST ALT &gt; 3 × ULN 3 . Total bilirubin &gt; 2 × ULN 4 . Autoimmune hepatitis 5 . Primary sclerosing cholangitis 6 . Known history alpha1Antitrypsin deficiency 7 . Known history chronic viral hepatitis 8 . Creatine kinase ULN 9 . Serum creatinine ULN 10 . For female , pregnancy breastfeed 11 . Use colchicine , methotrexate , azathioprine , systemic steroid two month precede screen 12 . Current use fibrates , include fenofibrates , simvastatin 13 . Use experimental treatment PBC 14 . Use experimental unapproved immunosuppressant 15 . Any condition ( ) would compromise safety subject compromise quality clinical study , judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PBC</keyword>
</DOC>